MX2012002131A - Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico. - Google Patents

Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico.

Info

Publication number
MX2012002131A
MX2012002131A MX2012002131A MX2012002131A MX2012002131A MX 2012002131 A MX2012002131 A MX 2012002131A MX 2012002131 A MX2012002131 A MX 2012002131A MX 2012002131 A MX2012002131 A MX 2012002131A MX 2012002131 A MX2012002131 A MX 2012002131A
Authority
MX
Mexico
Prior art keywords
recombinant adenovirus
adenovirus
plasmodium circumsporozoite
protein
modification
Prior art date
Application number
MX2012002131A
Other languages
English (en)
Other versions
MX339830B (es
Inventor
Takayuki Shiratsuchi
Moriya Tsuji
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of MX2012002131A publication Critical patent/MX2012002131A/es
Publication of MX339830B publication Critical patent/MX339830B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a modificaciones de proteínas de adenovirus para aumentar la respuesta inmune a un transgen de un adenovirus recombinante y a eludir inmunidad anti5 adenovirus preexistente. Algunas modalidades se refieren a un adenovirus recombinante derivado de un vector de plásmido de adenovirus recombinante, en donde el vector de plásmido de adenovirus recombinante comprende una secuencia de nucleótidos que codifica una proteína de circumsporozoito de Plasmodium, o porción antigenética de la misma, operablemente unidas a un promotor heterólogo y una proteína cápsida o núcleo modificada, en donde un epítope inmunogénico de circumsporozoito de Plasmodium se inserta en o reemplaza al menos parte de una proteína cápsida o núcleo. Otras modalidades se refieren a una composición farmacéutica o composición de vacuna contra la malaria que comprende un adenovirus recombinante según las modalidades anteriores. Modalidades adicionales incluyen un método de tratamiento, prevención, o diagnóstico de la malaria, que comprende la administración de una cantidad terapéutica de la composición farmacéutica o composición de vacuna de la malaria de conformidad con la modalidad anterior.
MX2012002131A 2009-08-18 2010-08-18 Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico. MX339830B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/054212 WO2011022002A1 (en) 2009-08-18 2009-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
PCT/US2010/045952 WO2011022522A1 (en) 2009-08-18 2010-08-18 Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

Publications (2)

Publication Number Publication Date
MX2012002131A true MX2012002131A (es) 2012-04-11
MX339830B MX339830B (es) 2016-06-13

Family

ID=43607237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002131A MX339830B (es) 2009-08-18 2010-08-18 Modificacion de adenovirus recombinante con epitopes de proteina de circumsporozoito deplasmodium inmunogenico.

Country Status (16)

Country Link
US (1) US20170348405A1 (es)
EP (2) EP3412306A3 (es)
JP (2) JP5947719B2 (es)
KR (1) KR20120094469A (es)
CN (2) CN105770880A (es)
BR (1) BR112012003808A2 (es)
CA (1) CA2769415A1 (es)
IL (1) IL217709A (es)
MX (1) MX339830B (es)
NZ (1) NZ598703A (es)
PH (1) PH12012500164A1 (es)
RU (1) RU2585228C2 (es)
SG (2) SG10201404970PA (es)
UA (1) UA108081C2 (es)
WO (2) WO2011022002A1 (es)
ZA (1) ZA201201286B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9115205B2 (en) 2010-10-18 2015-08-25 The United States Of America, As Represented By The Secretary Of The Army Plasmodium falciparum circumsporozoite vaccine gene optimization for soluble protein expression
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3004348B1 (en) * 2013-06-03 2023-03-08 VLP Therapeutics, Inc. Malaria vaccine
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
AU2016322544B2 (en) * 2015-09-16 2022-08-25 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
LT3405582T (lt) 2016-01-21 2020-12-10 Janssen Vaccines & Prevention B.V. Patobulinta vakciną nuo maliarijos adenoviruso, koduojančio ir eksponuojančio maliarijos antigeną, pagrindu
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
JP7794421B2 (ja) 2016-12-12 2026-01-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
CN108192876A (zh) * 2017-12-07 2018-06-22 东莞市第八人民医院 一种人3型腺病毒衣壳蛋白同时展示ca16双中和抗原表位疫苗候选株的制备方法和应用
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
JP2021178021A (ja) * 2020-05-14 2021-11-18 株式会社三洋物産 遊技機
WO2022234276A1 (en) * 2021-05-04 2022-11-10 SpyBiotech Limited Adenoviral vectors and vaccines thereof
JP2024536835A (ja) * 2021-09-23 2024-10-08 サジタリウス バイオ，インコーポレーテッド アデノウイルス及びアデノウイルスの使用方法
CN120944926B (zh) * 2025-10-15 2026-01-30 华中科技大学同济医学院附属同济医院 衣壳表面展示超大片段抗原的重组腺病毒、构建方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066623A (en) * 1993-11-23 2000-05-23 The United States Of America As Represented By The Secretary Of The Navy Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
PL376792A1 (pl) * 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2524499A1 (en) * 2003-05-14 2004-11-25 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Broadening adenovirus tropism
JP2005287309A (ja) * 2004-03-31 2005-10-20 Dnavec Research Inc 遺伝子導入を増強するための薬剤および方法
CN101072879B (zh) * 2004-10-13 2011-05-11 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用
WO2007027860A2 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
US20100272753A1 (en) * 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines

Also Published As

Publication number Publication date
PH12012500164A1 (en) 2022-03-09
JP2016146837A (ja) 2016-08-18
SG10201404970PA (en) 2014-10-30
JP6293181B2 (ja) 2018-03-14
KR20120094469A (ko) 2012-08-24
US20170348405A1 (en) 2017-12-07
HK1179508A1 (zh) 2013-10-04
CN103025349A (zh) 2013-04-03
JP5947719B2 (ja) 2016-07-06
JP2013502221A (ja) 2013-01-24
EP3412306A2 (en) 2018-12-12
EP3412306A3 (en) 2019-01-02
CA2769415A1 (en) 2011-02-24
SG178476A1 (en) 2012-03-29
WO2011022522A1 (en) 2011-02-24
EP2467157A4 (en) 2014-01-22
NZ598703A (en) 2014-04-30
AU2010286187A1 (en) 2012-02-16
IL217709A (en) 2016-05-31
EP2467157A1 (en) 2012-06-27
BR112012003808A2 (pt) 2016-11-16
UA108081C2 (uk) 2015-03-25
RU2585228C2 (ru) 2016-05-27
CN105770880A (zh) 2016-07-20
RU2012110255A (ru) 2013-09-27
WO2011022002A1 (en) 2011-02-24
CN103025349B (zh) 2016-05-18
ZA201201286B (en) 2013-05-29
MX339830B (es) 2016-06-13
IL217709A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
PH12012500164A1 (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
Bråve et al. Vaccine delivery methods using viral vectors
WO2011112945A3 (en) Foot and mouth disease virus recombinant vaccines and uses thereof
WO2009143167A3 (en) Dual delivery system for heterologous antigens
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
WO2010115133A3 (en) Newcastle disease virus vectored avian vaccines
WO2003072719A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
JP2016146837A5 (es)
WO2004096993A3 (en) Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
CN118576699A (zh) Hbv疫苗
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
WO2010068968A8 (en) Methods and compositions for use of a coccidiosis vaccine
WO2010044919A3 (en) Smallpox dna vaccine and the antigens therein that elicit an immune response
SI2538972T1 (en) Recombinant CDV compositions and their uses
AU2023258457B2 (en) Live-attenuated flaviruses with heterologous antigens
MX377650B (es) Vacuna y métodos para reducir una infección por campylobacter.
WO2008086386A3 (en) Adenoviral vector-based malaria vaccines
WO2012118559A3 (en) Tetravalent and mixed head bivalent dengue vaccine
JP2019506168A5 (es)
MX354752B (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2008127307A3 (en) Induction of an immune response against dengue virus using prime-boost approach
WO2012027473A2 (en) Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
JP2011088864A (ja) インフルエンザウイルスに対するベクターワクチン

Legal Events

Date Code Title Description
FG Grant or registration